The New Era of Inflammatory Disease Management Through the Application of Biosimilar Therapeutics

Program Dates: March 31st, 2023 - March 30th, 2024
Credits: 1.50 CPE Contact Hours (0.15 CEUs); 1.50 AMA PRA Category 1 Credits™

The New Era of Inflammatory Disease Management Through the Application of Biosimilar Therapeutics

Program Overview

While biosimilar therapeutics have been widely available for some time for the treatment inflammatory conditions, many pharmacists, managed care professionals, and other healthcare providers have not had a recent opportunity to investigate data showing the interchangeable safety and efficacy alignment between approved biosimilar therapeutics and their less accessible referent medications. In addition to interchangeability, concepts involving extrapolation and the shifting of a treatment plan to include biosimilar equivalents may not have made clear inroads into the daily practice of those involved in medication distribution and formulary management.  A clinical update on these concepts for pharmacists, managed care professionals, and related healthcare providers, can help reduce or remove serious barriers to care affecting patients with inflammatory bowel and joint diseases.

Target Audience

Pharmacists, managed care specialists, gastroenterologists, rheumatologists, nurses, and other health care professionals involved in the treatment of patients with inflammatory conditions, as well as patients with these conditions


I. Biosimilar Therapies for Inflammatory Disease: Pharmacologic Developmental Process and Assessment of Available Treatments
II. Clinical Trial Data Update and Practical Approaches for the Use of Biosimilars, Including Interchangeability and Switching
III. The Pharmacist and Managed Care Professional’s Role in Patient Education, Including Issues of Varying Patient Perceptions
IV. Expert Panel Discussion

Learning Objectives

  1. Review current on the developmental and clinical trial process of biosimilar therapies and recent advances in the use of biosimilars to treat inflammatory bowel disease and rheumatological disorders.
  2. Analyze recent clinical trial data and review practical approaches for the use of biosimilars, including interchangeability and switching.
  3. Develop strategies to communicate with the interprofessional team and educate patients on biosimilars, including issues of varying patient perceptions.


Shubha Bhat, PharmD
Clinical Pharmacy Specialist, Gastroenterology
Digestive Disease & Surgery Institute
Cleveland Clinic
Cleveland, Ohio


Adam S. Cheifetz, MD
Professor of Medicine
Harvard Medical School
Director, Center for Inflammatory Bowel Disease
Beth Israel Deaconess Medical Center
Boston, Massachusetts


Amanuel Kehasse, PharmD, PhD
Clinical Pharmacy Specialist in Rheumatology,
Dermatology, and Interstitial Lung Disease
Boston Medical Center Health System
Boston, Massachusetts


Disclosures of Relevant Financial Relationships

It is the policy of AcademicCME that all faculty, instructors, and planners disclose relevant financial relationships relating to the topics of this educational activity. Any relevant financial relationships are mitigated via a content review by planning committee members and faculty with no relevant financial relationships.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CE activity:

Faculty Relationship Identified With:
Shubha Bhat, PharmD


Consultant/Advisor: Boehringer Ingelheim International GmbH; Bristol-Myers Squibb Company; Pfizer Inc.; Pharmacosmos A/S; Prometheus Laboratories

Speaker’s Bureau: Prometheus Laboratories

Adam Cheifetz, MD


Consultant/Advisor: AbbVie Inc.; Artizan Biosciences, Inc.; Artugen Therapeutics; Bristol-Myers Squibb Company; Clairo; Food is Good; Equillium Bio; Fresenius Kabi AG; Fzata, Inc.; Janssen Global Services, LLC; Pfizer Inc.; Precise Pharma; Prometheus Laboratories; Protagonist Therapeutics Inc.; Samsung Biologics; Spherix Global Insights; Takeda Pharmaceutical Company Limited
Amanuel Kehasse, PharmD


Consultant/Advisor: Novartis Pharmaceuticals Corporation

Planners and Peer Reviewers

Timothy Hayes, MD, PhD; Kim Cheramie, MSN, RN-BC; Nicole McMenamin and Chelsey Simonds hereby state that they or their spouse/life partner do not have any relevant financial relationships to products or devices with any commercial interests related to the content of this activity of any amount during the past 12 months.

Accreditation Statement

In support of improving patient care, AcademicCME is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.



Credit Designation Statements

AcademicCME designates this continuing education activity for 1.50 CPE Contact Hours (0.15 CEUs) of continuing pharmacy education credit (UAN #JA4008190-0000-23-005-H01-P).

AcademicCME designates this enduring material for a maximum of 1.50 AMA PRA Category 1 Credits TM.

Clinicians should claim only the credit commensurate with the extent of their participation in the activity.

Financial Support

This activity has been supported by an independent educational grant from Pfizer Inc.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. AcademicCME and Pfizer Inc. do not recommend the use of any agent outside of the labeled indications.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Method of Participation

In order to claim credit, participants must complete the following:

  1. Read the learning objectives, accreditation information and faculty disclosures at the beginning of this activity.
  2. Complete the Pre-Activity Questions
  3. Read or Review the activity content.
  4. Complete the Post-Activity Test Questions and Evaluation.
  5. Learners who receive a grade of 60% or better on the Post-Activity Test Questions and complete the Evaluation will receive appropriate credit as indicated (CME, CNE, and/or CPE credit).
  • CME and CNE credit will be issued appropriate certificate of completion.
  • Others may request a “certificate of completion”.
  1. Learners should claim only the credit commensurate with the extent of their participation in the activity.

CE Inquiries/Special Needs

For all CE inquiries or special needs, please contact [email protected].


Provided by: AcademicCME-web